WeVote
Log In

Bill

Bill

S 3788

CLEAR LABELS Act

119th Congress Introduced by Katie Britt and 11 co-sponsors

Requires drug labels to disclose original manufacturer and full supply chain information to improve pharmaceutical traceability and reduce counterfeit/contaminated drug risks.

Committee on Health, Education, Labor, and Pensions. Hearings held.
1
WeVote Research Nonpartisan
Bill Summary · S 3788

Legislative bill overview

S 3788 would amend the Federal Food, Drug, and Cosmetic Act to require pharmaceutical drug labels to include information about the original manufacturer and the complete supply chain pathway. This transparency requirement would apply to drugs distributed in the United States, creating a traceability system from initial production through final dispensing.

Why is this important

Drug supply chain transparency addresses real concerns about counterfeit medications, contaminated drugs, and unauthorized generic substitutions that can reach consumers. During public health emergencies or product recalls, clear supply chain documentation enables faster identification and removal of problematic drugs from circulation, potentially protecting patient safety and reducing harm from compromised pharmaceuticals.

Potential points of contention

  • Compliance costs and complexity: Manufacturers may argue that extensive labeling requirements and supply chain documentation increase production costs, potentially raising drug prices for consumers and creating administrative burdens, particularly for smaller manufacturers
  • Trade secrets and competitive concerns: Pharmaceutical companies may resist disclosing detailed supply chain information, claiming it reveals proprietary manufacturing processes, sourcing decisions, and business relationships to competitors
  • International supply chain feasibility: Many drugs rely on multi-country ingredient sourcing and manufacturing; requiring complete traceability documentation may be logistically challenging and could complicate imports, potentially limiting drug availability or delaying FDA approvals

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.